Acro Biomedical Co., Ltd.

AI-generated fair value estimate for this company.

Method: Net asset value / liquidation approach: per the March 31, 2026 10-Q, total assets of $3,873 (all cash) minus total liabilities of $431,108 (mostly $375,108 in related-party payables) equal a stockholders' deficit of $(427,235); NAV per share floored at $0.00 against 60,042,000 shares outstanding.

Reasoning: Acro Biomedical's cordyceps-supplement business has had zero revenue since Q4 2022, no inventory, no employees beyond a part-time CEO, and recurring going-concern doubt with negative net worth, so no cash-flow method applies; liquidation NAV is the only defensible approach and correctly signals de minimis intrinsic value.